PDCD1 and cancer: In the most extensive single-center study conducted to date, Drobni et al. compared 2842 patients receiving various ICIs (primarily PD-1 inhibitors) with controls matched for age, cancer type, and CV history, assessing the risk of ASCVD-related events over a 2-year follow-up.